The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH

In our exclusive interview, Dr Morgans detailed the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide (Nubeqa) for this population. She discussed treatment considerations for determining whether to give docetaxel along with darolutamide; other factors to remember with AR inhibition; and the need to continue driving consensus across practices in the management of prostate cancer.